Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

What do I need to know about immunoglobulin light chain (AL) amyloidosis?

Blood Reviews, 4, 26, pages 137 - 154

Abstract

Immunoglobulin light chain (AL) amyloidosis is the most common acquired systemic amyloidoses. Its presentation is often insidious and progressive, which may delay diagnosis. The interval between first symptoms and actual diagnosis along the intrinsic heterogeneity of tissue tropism create a wide spectrum of presentations, both in terms of scope and depth of symptoms and signs and functional status of patients. In this review, the authors review the pathogenesis, diagnosis and differential diagnosis of AL amyloidosis along with the prognosis and state-of-the-art management for patients with this affliction.

Keywords: Amyloidosis, Multisystem disease, Monoclonal gammopathy, Prognosis, Transplantation.

Footnotes

Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States

lowast Corresponding author. Tel.: + 1 507 284 2176; fax: + 1 507 266 4972.

1 Tel.: + 1 507 284 2865; fax: + 1 507 266 4972.

2 Tel.: + 1 507 284 2017.